Published in Expert Opin Drug Metab Toxicol on December 19, 2011
Transfusion-dependent low-risk myelodysplastic patients receiving deferasirox: Long-term follow-up. Oncol Lett (2013) 0.80
Polymeric nanocarriers for the treatment of systemic iron overload. Mol Cell Ther (2015) 0.76
Clinically approved iron chelators influence zebrafish mortality, hatching morphology and cardiac function. PLoS One (2014) 0.75
Safety and tolerability of deferasirox in pediatric hematopoietic stem cell transplant recipients: one facility's five years' experience of chelation treatment. Oncotarget (2017) 0.75
Beta-thalassemia. Orphanet J Rare Dis (2010) 3.06
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica (2006) 2.54
Onset of cardiac iron loading in pediatric patients with thalassemia major. Haematologica (2008) 1.24
Combined iron chelation therapy. Ann N Y Acad Sci (2010) 1.06
No evidence of cardiac iron in 20 never- or minimally-transfused patients with thalassemia intermedia. Haematologica (2008) 0.88
Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen. J Clin Pharmacol (2008) 0.88
Natural history of hepatitis C in thalassemia major: a long-term prospective study. Eur J Haematol (2013) 0.85
Once-daily oral deferasirox for the treatment of transfusional iron overload. Expert Rev Clin Pharmacol (2008) 0.83
Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia. Br J Haematol (2014) 0.81
Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up. Haematologica (2014) 0.80
Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox. Eur J Haematol (2014) 0.80
A decisional algorithm to start iron chelation in patients with beta thalassemia. Haematologica (2014) 0.78
Seasonal variation of pretransfusion hemoglobin levels in patients with thalassemia major. Blood (2005) 0.77
Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study. Br J Haematol (2014) 0.77
The Problem of Borderline Hemoglobin A2 Levels in the Screening for β-Thalassemia Carriers in Sardinia. Acta Haematol (2016) 0.77
Sudden cardiac failure in a beta-thalassemia major patient receiving chemotherapy for acute promyelocytic leukemia. Leuk Lymphoma (2007) 0.75
Thalassemia Major: Who Is Afraid of Serum Ferritin below 500 μg/l? Acta Haematol (2015) 0.75
Investigating the alpha1(NcoI) mutation. Acta Haematol (2014) 0.75